Price
No data yet.
Social Signal Score
Revenue
$7.02M+1436.32%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Ilan Danieli
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 61
- Beta
- 1.33
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- -1.83
Financials
Revenue
$7.02M+1436.3%Net Income
$-219.0KEBITDA
$-95.0KFree Cash Flow
$528.0KEPS (diluted)
$-0.12Shares Outstanding (diluted)
1.79M+62436.5%Operating Expenses
$3.73MCash & Debt
$3.08MReturn of Capital
$29.0KRevenue by Segment (annual)
$72.26MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $24.05M | $-363.0K | $-0.23 |
| 2024 | $15.96M | $-4.29M | $-2.93 |
| 2023 | $15.20M | $-5.85M | $-4.51 |
| 2022 | $9.41M | $-12.20M | $-10.73 |
| 2021 | $8.85M | $-8.55M | $-8.10 |
| 2020 | $6.09M | $-10.63M | $-14.84 |
| 2019 | $3.13M | $-13.24M | $-46.51 |
| 2018 | $2.86M | $-15.69M | $-217.81 |
| 2017 | $1.72M | $-20.69M | $-1338.20 |
| 2016 | $1.56M | $-7.62M | $-580.93 |
| 2015 | $1.65M | $-32.95M | $-870.12 |
| 2014 | $27.08M | $-13.94M | $-837.26 |
| 2013 | $27.54M | $-15.99M | $-990.09 |
| 2012 | $31.48M | $-8.33M | $-646.66 |
Valuation
PRPOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (5)
- Newszacks.com·13d ago·Neutral
PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now? Precipio and Fulgent Genetics differ in business scope, valuation and growth drivers, but which cancer diagnostics stock looks more compelling now? Let's dive in.
View source ↗ - Newszacks.com·42d ago·Positive
PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now? Precipio and Biodesix take different approaches to cancer diagnostics, but which stock looks more compelling now? Let's dive in.
View source ↗ - Newszacks.com·45d ago·Positive
Precipio Stock Gains Post Q2 Earnings, Revenue Momentum Strong PRPO's second-quarter 2026 revenue momentum strengthens on higher diagnostic volumes and record product sales, alongside positive adjusted EBITDA and cash generation.
View source ↗ - Newsseekingalpha.com·49d ago·Positive
Precipio, Inc. (PRPO) Q2 2026 Earnings Call Transcript Precipio, Inc. (PRPO) Q2 2026 Earnings Call Transcript
View source ↗ - Newsglobenewswire.com·52d ago·Neutral
Precipio Announces Q2-2026 Financial Results Revenue reaches quarterly record as Precipio returns to positive Adjusted EBITDA and strengthens cash position Revenue reaches quarterly record as Precipio returns to positive Adjusted EBITDA and strengthens cash position
View source ↗
Earnings
Mon, Nov 16(in 6 weeks)
Consensus estimate $-2.00 per share
Typical surprise -106.8% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-0.12 vs $-2.00beat
- Fri, Nov 14$-0.05 vs $0.74miss
- Wed, Aug 13$0.05 vs $0.74miss
- Wed, May 14$-0.59 vs $0.40miss
- Thu, Mar 27$-0.23 vs $0.74miss
Estimates and results for PRPO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PRPO officers and directors.
- Bought
- $318k
- Sold
- $393k
18 trades
9 trades
- Sandberg Richard Asold
- Sandberg Richard Asold
- Sandberg Richard Asold
- Sandberg Richard Asold
- Sabet Ahmed Zakibought
- Sabet Ahmed Zakibought
- Sabet Ahmed Zakibought
- Sabet Ahmed Zakibought
73 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PRPO.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.